Patents Examined by Misook Yu
  • Anti-ERBB2 antibody adjuvant therapy
    Patent number: 8591897
    Abstract: The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.
    Type: Grant
    Filed: April 6, 2006
    Date of Patent: November 26, 2013
    Assignee: Genentech, Inc.
    Inventor: John L. Bryant
  • Degraded TPO agonist antibody
    Patent number: 8586039
    Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: November 19, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunoda, Tetsuro Orita
  • Engineered antibody constant domain molecules
    Patent number: 8580927
    Abstract: Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: November 12, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Dimiter S. Dimitrov
  • Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
    Patent number: 8557244
    Abstract: This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: October 15, 2013
    Assignee: Biogen Idec Inc.
    Inventors: Christine White, Antonio Grillo-Lopez
  • Pharmaceutical preparations and methods for inhibiting tumors
    Patent number: 8551951
    Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: October 8, 2013
    Assignee: Aenorasis SA Pharmaceuticals and Medical Devices
    Inventors: Seema Garde, Chandra J. Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
  • Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
    Patent number: 8551474
    Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ?-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: October 8, 2013
    Assignee: Central Iowa Health System
    Inventors: Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
  • Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
    Patent number: 8535658
    Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ? (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ? galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: September 17, 2013
    Assignee: Central Iowa Health System
    Inventors: Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
  • Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
    Patent number: 8529901
    Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: September 10, 2013
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Max Hasmann, Helmut Lenz, Werner Scheuer
  • Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
    Patent number: 8524491
    Abstract: Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/neu oncogene is associated.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: September 3, 2013
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Martin A Cheever, Mary L Disis
  • 88kDa tumorigenic growth factor and antagonists
    Patent number: 8512960
    Abstract: This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: August 20, 2013
    Assignee: A&G Pharmaceutical, Inc.
    Inventor: Ginette Serrero
  • Methods and compositions useful in the treatment of mucositis
    Patent number: 8497243
    Abstract: In certain aspects, the present invention provides compositions and methods for treating mucositis.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: July 30, 2013
    Assignee: Promedior, Inc.
    Inventors: David Paul Hesson, Michael Scott Kramer
  • Human beta-glucuronidase mutants with elevated enzymatic activity under physiological conditions and method for identifying such
    Patent number: 8491891
    Abstract: A number of human beta-glucuronidase variants having higher enzymatic activity at physiological pH as compared with wild-type beta-glucuronidase and uses thereof in prodrug therapy. Also disclosed herein is a method for identifying enzyme variants having elevated enzymatic activity using a mammalian surface display system.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: July 23, 2013
    Assignee: Academia Sinica
    Inventors: Steve Roffler, Chia-Hung Wu, Wolfgang Schechinger, Kai-Chuan Chen, Zeljko Prijovic
  • Immunity to folate receptors
    Patent number: 8486412
    Abstract: This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FR? immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: July 16, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Keith L. Knutson, Lynn C. Hartmann, Kimberly R. Kalli, Christopher J. Krco
  • Alpha-emitting constructs and uses thereof
    Patent number: 8486409
    Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: July 16, 2013
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Dangshe Ma, George Sgouros
  • Monoclonal antibody therapy for pancreas cancer
    Patent number: 8470326
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: June 25, 2013
    Assignee: Precision Biologics
    Inventors: Myron Arlen, Kwong Tsang
  • Composition for treating cancer and use thereof
    Patent number: 8450283
    Abstract: The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: May 28, 2013
    Assignee: National Taiwan University
    Inventors: Pan-Chyr Yang, Tse-Ming Hong, Yuh-Ling Chen, Ang Yuan, Yi-Ying Wu
  • Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
    Patent number: 8444983
    Abstract: The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: May 21, 2013
    Assignee: Quark Pharmaceuticals, Inc.
    Inventor: Elena Feinstein
  • Purified hemocyanin obtained from ; subunit of purified hemocyanin; use of hemocyanin, its subunit or immunogenic fragments and compositions containing the same
    Patent number: 8436141
    Abstract: The invention relates to purified hemocyanins, subunits or immunogenic fragments thereof, wherein the hemocyanins are purified from a hemolymph of Fissurella latimarginata (black limpet), Fissurella cumingi (strawberry limpet), or Fissurella maxima (queen limpet). The invention also relates to compositions including the purified hemocyanins and methods of treating neoplastic diseases by administering such compositions.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: May 7, 2013
    Assignee: Biosonda S.A.
    Inventor: Maria Inés Becker
  • Methods and compositions for topoisomerase I modulated tumor suppression
    Patent number: 8431353
    Abstract: Disclosed herein are methods and compositions for determining the sensitivity or enhancing the sensitivity of cells to the effects of topoisomerase I inhibitors. Also disclosed are methods and compositions for inducing cell death, apoptosis and/or growth arrest which may be used for tumor suppression.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: April 30, 2013
    Assignee: RG Biopharma LLC
    Inventors: Ruth A. Gjerset, Keya Bandyopadhyay
  • Method of assessing colorectal cancer status in an individual
    Patent number: 8426140
    Abstract: The invention relates to a method of screening a patient to identify and quantify risk of colorectal cancer, and thereby identify patients suitable for further invasive investigation such as a colonoscopy. The method employs auto-antibodies that are shown to correlate with colorectal cancer risk method and involves of assaying a biological sample from the individual for a combination of a plurality of biomarkers selected from SEQUENCE ID NO's: 1 to 12, where the combination of biomarkers is chosen such that detection of all biomarkers in the patient correlates to at least a 50% risk of the patient being positive for colorectal cancer. Detection of all of the combination of biomarkers indicates that the patient should undergo a colonoscopy. Kits for performing the method of the invention are also provided.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: April 23, 2013
    Assignee: Royal College of Surgeons in Ireland
    Inventors: Gregor Kijanka, Dermot Kenny, Elaine Kay